Scroll Down

hero
2018 AASLD GUIDANCE RECOMMENDS OCALIVA as the only approved second-line treatment option for PBC patients who have not achieved their treatment goal with UDCA alone or cannot tolerate UDCA1 SEE THE GUIDELINES

AASLD, American Association for the Study of Liver Diseases; PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid.

Significant, Sustained Alkaline Phosphatase Reductions2

OCALIVA® (obeticholic acid) efficacy OCALIVA® (obeticholic acid) efficacy

When used in combination with UDCA or as monotherapy, OCALIVA delivered significant and sustained reductions in alkaline phosphatase2,b

See the efficacy data

bSignificant efficacy in patients achieving the primary endpoint, defined as alkaline phosphatase <1.67x the upper limit of normal (ULN), an alkaline phosphatase decrease ≥15%, and total bilirubin ≤ ULN.

ALP, alkaline phosphatase.

Dosing for OCALIVA

Starting dose for OCALIVA is 5 mg once daily for non-cirrhotic or compensated Child-Pugh Class A patients. Up-titrate as recommended based on tolerability and response.

Starting dose for patients with Child-Pugh Class B or C, or a prior decompensation event, is 5 mg once weekly.

Learn More About Dosing

OCALIVA obeticholic acid OCALIVA obeticholic acid

Enroll for updates

Get the emails you want about OCALIVA:

  • You choose the topics
  • Content is intended for US healthcare professionals

REGISTER FOR UPDATES

Register for Updates Close

*Required fields. Invalid entry. Please try again.

First name required
Last name required
Email required
Specialty Profession required


REGISTER


 

Thank you for your interest

References:

  1. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases [published online August 3, 2018]. Hepatology. doi: 10.1002/hep.30145.
  2. OCALIVA [package insert]. New York, NY: Intercept Pharmaceuticals, Inc.; 2018.
  3. URSO [package insert]. Bridgewater, NJ: Aptalis Pharma US, Inc.; 2013.
OCALICA obeticholic acid

Enroll for updates

REGISTER FOR UPDATES

Register for Updates Close

*Required fields. Invalid entry. Please try again.

First name required
Last name required
Email required
Specialty Profession required


REGISTER


 

Thank you for your interest

OCALIVA® (obeticholic acid)

Patient Assistance: 1-844-622-4278

This site is intended for US healthcare professionals only Home Visit Patient Site Prescribing Information Important Safety Information

Patient Assistance:
1-844-622-4278

You are about to leave Ocalivahcp.com

Click CONTINUE to go to the page you requested or click CANCEL to remain on this page.

Cancel Continue